# Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

> **NCT05442216** · PHASE2 · RECRUITING · sponsor: **Joshua Zeidner** · enrollment: 53 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Tagraxofusp
- **DRUG:** Azacitidine
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT05442216
- **Lead sponsor:** Joshua Zeidner
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2030-07-21
- **Final completion:** 2031-07-21
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05442216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05442216, "Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05442216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*